ALK and non-small cell lung carcinoma: Nevertheless, the identification of therapeutically targetable driver mutations like activating mutations in the epidermal growth factor receptor (EGFR) and rearrangements of the ALK oncogene and the subsequent introduction of personalized treatment approaches has improved outcome of these genetically defined NSCLC subgroups within the last decade [1-5].